ViGenCell

ViGenCell Current Liabilities

The Current Liabilities of ViGenCell (308080.KQ) as of Oct 19, 2026 is -940.00 KRW. In the previous year, Current Liabilities was 7.63 B KRW — a change of -100.00% (lower).

Current Liabilities

-940.00KRW

YoY

-100.00%

Last updated:

Current Liabilities of ViGenCell is 2025 -940.00 KRW. Current Liabilities of ViGenCell was 2024 7.63 B KRW. It decreases by -100.00% lower compared to the previous year.

The ViGenCell Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
35.47 B KRW
Jan 1, 2020
39.83 B KRW
Jan 1, 2021
10.19 B KRW
Jan 1, 2022
8.35 B KRW
Jan 1, 2023
7.63 B KRW
Jan 1, 2024
7.63 B KRW
Jan 1, 2025
-940.00 KRW
The ViGenCell Current Liabilities history
YEARCurrent LiabilitiesYoY
-940.00KRW-100.00%
7.63 BKRW+0.08%
7.63 BKRW-8.69%
8.35 BKRW-18.02%
10.19 BKRW-74.42%
39.83 BKRW+12.30%
35.47 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViGenCell Stock analysis

What does ViGenCell do? ViGenCell Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company has 80 employees and completed its initial public offering (IPO) on August 25, 2021. ViGenCell focuses on research and development in natural science and engineering, with a particular emphasis on cell therapy technologies. The company develops and manufactures immuno-cancer cell therapy products and immunosuppressive cell therapy products. It also provides the Vitier platform, which is an antigen-specific killing T cell treatment, the Viranger platform for gamma delta T cell gene therapy, and the Vimedier platform-based technology for myeloid suppressor cell therapy derived from umbilical cord blood. ViGenCell is engaged in the research and development of new drugs targeting conditions such as acute myeloid leukemia (AML) and glioblastoma. The company's website is https://www.vigencell.com/. ViGenCell Inc is listed on the Korean stock market under the ticker 308080.KQ and has the ISIN KR7308080001. The company's headquarters are located in Seoul, South Korea. ViGenCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViGenCell stock

Current Liabilities of ViGenCell is -940.00 KRW in 2025.

Current Liabilities of ViGenCell changed from 7.63 B KRW to -940.00 KRW, representing a -100.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities ViGenCell since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's ViGenCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ViGenCell

All Key Metrics — ViGenCell